Omega Fund IV, L.P.

Omega Fund IV, L.P. has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Replimune Group, Inc., Kezar Life Sciences, Inc. and Translate Bio, Inc. Between 25 June 2018 and 16 March 2022, the trades on record add up to 44 filings.

Both buying and selling appear: 2 purchases worth €6.1M, against 30 sales worth €11.1M. Sales outweigh purchases by €5.0M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 option exercise. Since January 2022: no purchases and 4 sales on the market.

Most recently, on 16 March 2022, the filings show an open-market sale worth €643k in Replimune Group, Inc. The latest purchase dates back some time: it was published 2,529 days ago, on 20 November 2019. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.